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Edited by Lukas HuberAbstract A statistical method for combining multiple micro-
array studies has been previously developed by the authors. Here,
we present the application of the method to our hepatocellular
carcinoma (HCC) data and report new ﬁndings on gene
expression changes accompanying HCC. From the cross-veriﬁ-
cation result of our studies and that of published studies, we found
that single microarray analysis might lead to false ﬁndings. To
avoid those pitfalls of single-set analyses, we employed our eﬀect
size method to integrate multiple datasets. Of 9982 genes
analyzed, 477 signiﬁcant genes were identiﬁed with a false
discovery rate of 10%. Gene ontology (GO) terms associated with
these genes were explored to validate our method in the biological
context with respect to HCC. Furthermore, it was demonstrated
that the data integration process increases the sensitivity of
analysis and allows small but consistent expression changes to be
detected. These integration-driven discoveries contained mean-
ingful and interesting genes not reported in previous expression
proﬁling studies, such as growth hormone receptor, erythropoi-
etin receptor, tissue factor pathway inhibitor-2, etc. Our ﬁndings
support the use of meta-analysis for a variety of microarray data
beyond the scope of this speciﬁc application.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Recently, many microarray results have been derived from
cancer studies with an increasing interest in the classiﬁcation of
tumors and prediction of clinical outcome. We present here a
meta-analysis result of expression proﬁles of hepatocellular
carcinoma (HCC), which is among the ﬁve leading causes of* Corresponding author. Fax: +82-42-879-8519.
E-mail address: sskimb@kribb.re.kr (S. Kim).
Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B
virus; GO, gene ontology; FEM, ﬁxed eﬀects model; REM, random
eﬀects model
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.03.081cancer death in the world. The causes of HCC are better un-
derstood than those of other cancers in human. Major risk
factors for HCC are chronic hepatitis resulting from hepatitis
B virus (HBV) or hepatitis C virus. Nevertheless, the molecular
pathogenesis of HCC, including changes in gene expression
and aberrations in gene structure as well, is not well under-
stood, leaving prognosis of HCC very poor.
We collected four independent cDNA microarray datasets
generated with a common objective to identify diﬀerentially
expressed genes in HBV-positive HCC samples. Despite the
fact that they had been created in relatively controlled exper-
imental conditions, we failed to directly merge the data even
after normalization of each dataset. A clustering result showed
that the tissue samples tended to cluster accordingly more to
their experimental origin (i.e., which dataset they were derived
from) rather than to their biological origin (i.e., whether they
are malignant or normal). As was pointed out by Brazma et al.
[1], a wide variety of experimental variables might have caused
this problem. These include microarray platforms and formats,
reference samples, experimental procedures, laboratory con-
ditions, parameters on image processing, and so on.
One way to draw a conclusion from these heterogeneous
datasets is to combine their analysis results using meta-analysis
methods [2–5]. There are three major approaches to meta-
analysis: vote counting, combining signiﬁcance levels, and
combining eﬀect sizes. Vote counting represents the result of
analysis as either a positive or negative vote to a hypothesis.
Suppose we have eight microarray datasets with a common
study design. The change in the expression level of a gene
caused by a given treatment might be signiﬁcant in ﬁve data-
sets and not signiﬁcant in three datasets, yielding ﬁve positive
and three negative votes. While intuitive, this is a rather crude
approach, and does not take into account the level of signiﬁ-
cance of an individual result. By combining signiﬁcance levels,
this limitation can be overcome. For the example in the above,
the P values can be combined across the eight datasets to
estimate the overall P value. Recently, this method was suc-
cessfully applied to the meta-analysis of four prostate cancer
microarray datasets making new ﬁndings [6,7]. The most
recent development in meta-analysis introduced the novel
concept of combining eﬀect sizes. It is a procedure that permitsation of European Biochemical Societies.
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estimate of the average eﬀect size. Eﬀect size is a name given to
a family of indices that measure the magnitude of treatment
eﬀect given in a study. In [8], a methodology for using eﬀect
size models for microarray data was established and shown to
be able to manage interstudy variation eﬀectively.
In the analysis of the multi-center HCC datasets, three main
questions were asked:
1. Do the independent studies produce similar results? Does a
typical single-set analysis with small sample size produce re-
producible results? To answer this question, we performed a
cross-veriﬁcation by comparing individual signiﬁcant gene
lists. We also compared ﬁve published HCC studies that
had been performed with laboratory scale sample size
[9–13].
2. Does the meta-analysis of microarray analyses work from
theory to practice? The question could be addressed by in-
vestigating gene ontology (GO) terms associated with the
dysregulated genes identiﬁed by meta-analysis. This would
also provide an overview of their biological implications
with regard to HCC.
3. What are the advantages of meta-analysis versus single
analyses? One of our expectations was that increased sam-
ple size would increase statistical power. By comparing
the meta-analysis result with the individual results, we
could specify the advantage of meta-analysis from the bio-
logical as well as from the statistical perspective. Further-
more, here we show that meta-analysis is essential for
making reliable results from microarrays.2. Materials and methods
2.1. Microarrays and sequence veriﬁcation
Human cDNA clone set (UniGEMTM) was obtained from Incyte
Genomics (Fremont, CA, USA). The identities of more than 10 000
individual clones were veriﬁed by single-pass sequencing. A total of
7844 sequences were generated after passing PHRED base calling and
quality control processes. About 5461 known genes and 994 ESTs,
including replicated ones, were conﬁrmed in the set by annotating with
UniGene (http://www.ncbi.nlm.nih.gov/UniGene).
2.2. Microarray experiments and datasets
HCC and adjacent normal samples were obtained with
informed consent from patients at three diﬀerent hospitals. All theTable 1
Dataset information
Dataset
ID
Number of tumor
samples
Number of normal
samples
Chip type Sam
(Cy5
P1 9 9 Membrane Rad
P2 6 8 Aﬀymetrix SAP
P3 20 20 cDNA Nor
P4 12 12 cDNA Tum
P5 8 8 cDNA Tum
D1 16 16 cDNA (Ver. 1) Sam
D2 23 23 cDNA (Ver. 1) Sam
D3 29 5 cDNA (Ver. 1) Sam
D4 12 9 cDNA (Ver. 2c) Plac
aRefs. [9–13].
b The human placenta RNA samples were from the same batch.
c Ver. 2 chips have diﬀerent spot locations from Ver. 1 chips. They were priHCC samples were HBV-positive. Each hospital’s Clinical Research
Review Board has approved its own study. The human cDNA
clone set was spotted using a commercial arrayer. Two diﬀerent ver-
sions diﬀering in terms of spot-locations were distributed to the hos-
pitals for four independent hybridizations of HCC and normal liver
samples. Sample preparation, microarray hybridizations, and ﬂuores-
cence signal acquisitions were carried out independently at each in-
stitution according to similar but not identical experimental protocols
and laboratory conditions. One experiment used a diﬀerent reference
sample from the three other experiments (see Table 1 for detailed in-
formation).
The raw data generated from these experiments were collected and
subjected to a normalization procedure after being passed a null value
and a variation ﬁlter. A lowess smoothing of the scatter plot between
log2 R=G and log2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R Gp was proposed recently [14]. We applied the
so-called ‘within-print-tip-group’ normalization method using the R
package available at http://www.stat.berkeley.edu/users/terry/zarray/
Html.
2.3. Eﬀect size method
The statistical method has been detailed in [8] and is described only
brieﬂy here. Standardizing the mean diﬀerence between the two groups
gives d ¼ Xt  Xnð Þ=Sp, where Xt and Xn represent the means of the
tumor and normal group, respectively, and Sp is the pooled standard
deviation. For each gene, we obtained the eﬀect size di for studies
i ¼ 1; 2; . . . ; k:
With a well-established model for combining eﬀect sizes, we easily
estimate the average eﬀect size l. The general model was given by
di ¼ lþ di þ ei, where di  Nð0; s2Þ and ei  Nð0; s2i Þ. Between-study
variance s2 represents the variability between studies, while within-
study variance s2i represents the sampling error conditioned on the ith
study. We let s2 ¼ 0 if we can safely assume that eﬀect sizes dis are not
originally diﬀerent from one another. This can be addressed by testing
for the homogeneity of study eﬀects. We used a widely used test for
homogeneity based on the statistic Q ¼Pwiðdi  dÞ2, where wi ¼ s2i
and d ¼ ðPwidiÞ=
P
wi [15]. Model selection led to an overall estimate
of l given by weighted average of the observed eﬀect sizes as
l^ ¼ ðPwidiÞ=
P
wi, where wi ¼ ðs2i þ s2Þ1, if s2i and s2 are known.
The estimation of s2i and s
2 was given in [8] with Bayesian approach.
Standard normal score for the average eﬀect size (zavg) was computed
by estimating the standard error of the average eﬀect size. Standard
normal score for each eﬀect size (zi) was computed as the ratio of di to
si.3. Results
3.1. Data collection and preliminary examinations
Four independent datasets (D1, D2, D3 and D4) were cre-
ated from multi-center microarray studies on HCC (Table 1).ple labeling
:Cy3)
Statistic Authora or experimenter
ioactivity Paired-sample fold
change
Xu et al. [11]
E Two-sample fold change Tackels-Horne et al. [10]
mal:tumor Paired-sample fold
change
Okabe et al. [9]
or:normal Paired-sample fold
change
Li et al. [12]
or:normal Paired-sample fold
change
Chung et al. [13]
ple:normal liver Two-sample eﬀect size Local hospital A
ple:placentab Two-sample eﬀect size Local hospital B
ple:placenta Two-sample eﬀect size Local hospital C
enta:sample Two-sample eﬀect size Local hospital C
nted using the same arrayer.
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dataset. The eﬀect size of a gene that has missing values in
greater than 50% of the observations in a particular dataset was
considered as missing for that dataset. Two gene sets, G1 and
G2, were deﬁned to contain genes or ESTs which generated all
four eﬀect sizes (6610 elements) and more than two eﬀect sizes
(9982 elements), respectively. G1, the subset of G2, was used as
default throughout this study.
On the other hand, we attempted to ﬁnd commonly reported
genes among ﬁve published studies, P1, P2, P3, P4 and P5
(Table 1). However, to our astonishment, no up-regulated gene
and only two down-regulated genes (cytochrome P450IIC,
polypeptide 9 and hepatocyte growth factor (HGF) activator)
were found. To quantify consistency between studies, cross-
veriﬁcations were performed as follows: ﬁrst, signiﬁcant genes
from each dataset were listed; second, in each list, we counted
the number of genes which appeared also in at least one of the
other lists; third, a veriﬁcation score was computed as the ratio
of the number of veriﬁed genes to the total number of the listed
genes. The procedure was applied between P1–P5 and between
D1–D4, separately. For D1–D4, a z score was assigned for
each gene and genes with z > 2:5 were identiﬁed as signiﬁcant
genes (the same threshold as used for our meta-analysis). As
shown in Table 2, the veriﬁcation scores were about 9–20% for
P1–P5 and 14–22% for D1–D4, which means that about 80%
of the genes called signiﬁcant in a single study were not con-
ﬁrmed by at least one of the other studies. This inconsistency is
most likely to be caused from diﬀerent experimental conditions
and limited scopes of study populations. This ﬁnding explicitly
presents the artifacts of single-set analyses and emphasizes the
importance of integrating multiple studies.
3.2. Model selection and the identiﬁcation of signiﬁcant genes
To explore variability between the studies, the heterogeneity
of the eﬀect sizes was measured by the statistic Q, which is
distributed as a v2 distribution under the hypothesis of ho-
mogeneity [15]. A quantile plot for the genes of G1 was shown
in Fig. 1(a) in [8]. The observed Q values perfectly ﬁtted the v23
distribution, implying the homogeneity of the eﬀect sizes. In
other words, the eﬀect sizes can be assumed to be sampled
from the common normal population, and the diﬀerences are
likely to be due to sampling error alone. Therefore, we could
consider the between-study variance s2 to be zero.
To estimate the statistical signiﬁcances of the average eﬀect
sizes without a normal approximation, we applied the recently
described analytical method called SAM [16]. The procedure
also includes adjusting for multiple testing. G2 was used in thisTable 2
Veriﬁcations of signiﬁcant gene lists from diﬀerent studies
Veriﬁcation Published gene lists
P1 P2 P3 P4 P5
No veriﬁcationa 68 80 176 66 42
Cross-veriﬁcationb 14 15 18 6 5
(% score) (20.6) (18.8) (10.2) (9.1) (11.9)
Meta veriﬁcationc NA NA NA NA NA
(% score) NA NA NA NA NA
Veriﬁcation scores are shown in boldface.
a Total number of genes present in each gene list.
bNumber of genes appeared in at least one of other gene lists (between P1–
cNumber of genes appearing in the meta-analysis result (for D1–D4) or numprocedure so that the genes with some missing results were
included. For each dataset, column-wise permutation was
performed to produce a null eﬀect size for each gene. Permu-
tations between datasets were not allowed to occur. These null
eﬀect sizes from the four datasets were combined under the
assumption that s2 is zero. In this way, the z score of the null
average eﬀect size, zavg, was obtained for each gene. The genes
with jzavgj > 2:5 from the original data were chosen. This cri-
terion identiﬁed 150 genes signiﬁcantly up-regulated and 327
genes signiﬁcantly down-regulated. For each permutation, the
number of the genes with jzavgj > 2:5 was counted. 300 diﬀer-
ent permuted datasets generated an average of 48.5 such genes.
The number implies an estimated number of falsely signiﬁcant
discoveries. The ratio over the number of signiﬁcant genes in
the original data, i.e., 477, yields an estimated false discovery
rate of 10%. The gene names and expression pattern of 393
known genes among 477 signiﬁcant genes can be visualized at
http://centi.kribb.re.kr/MMA. Complete datasets also can be
downloaded from the site.
3.3. Comparison of meta-analysis with individual analyses
Of the 477 signiﬁcant genes, 365 genes were found also in
G1. Using these 365 genes, we compared the meta-analysis
result with the individual analyses. Signiﬁcant genes in each
dataset were selected using the same z threshold (zth ¼ 2:5) as
that used in the meta-analysis. These gene lists are the ones
that were used in our cross-veriﬁcation described above. For
each of the gene lists, we counted the number of genes ap-
pearing in the list of the 365 genes. For the meta-analysis re-
sult, we counted the number of genes appearing in at least one
of the four lists. Veriﬁcation scores were generally higher than
those in cross-veriﬁcation (Table 2), which implies that the
meta-analysis produced results in reasonable agreement with
each individual analysis.
Notably, in contrast to the 215 genes present in at least one
of the individual lists, the other 150 genes were not found in
any of the lists. We denoted these genes as integration-driven
discoveries. As a general statement, among total discoveries
satisfying jzavgjP zth, those with jzij < zth for all studies
i ¼ 1; . . . ; k are called integration-driven discoveries with re-
gard to the zth.
They can be considered as being detected by the integration
process. The plot in Fig. 1 shows the relationship between the
number of integration-driven discoveries and the number of
total discoveries for up- or down-regulated genes. Of the most
signiﬁcant 500 genes in the meta-analysis, approximately up to
100 up- and 100 down-regulated genes could be detected byGene lists in this study
D1 D2 D3 D4 Meta-analysis
165 188 125 62 365
23 38 28 12 NA
(13.9) (20.2) (22.4) (19.4) NA
62 130 59 16 215
(37.6) (69.1) (47.2) (25.8) (58.9)
P5 and between D1–D4).
ber of genes appearing in at least one of D1–D4 (for meta-analysis).
Table 3
Biological aspects of the genes dysregulated in HCC
Gene ontologya Dysregulatedb Totalc ORd
Biological process 146 2145 1.0
Lipid metabolism 17 110 2.5
(Steroid metabolism) (9) (30) (5.9)
Amino acid and derivative
metabolism
7 37 3.2
Carbohydrate metabolism 7 58 1.9
Hormone metabolism 5 11 11.4
Biosynthesis 16 137 1.8
Circulation 8 34 4.2
Metal ion transport 5 38 2.1
Chemotaxis 5 41 1.9
Cell adhesion 9 90 1.5
Apoptosis 9 92 1.5
Intracellular signaling cascade 13 99 2.1
(Small GTPase mediatedsignal
transduction)
(5) (19) (4.9)
Molecular function 155 2161 1.0
Complement component 5 9 16.2
Enzyme activator 6 39 2.4
Enzyme inhibitor 5 47 1.5
Serin-type peptidase 5 39 1.9
Transferase, transferring
hexosyl groups
6 24 4.3
Oxidoreductase 11 106 1.5
Receptor signaling protein 9 88 1.5
(Small GTPaseregulatory/
interacting protein)
(5) (35) (2.2)
Cellular component 118 1729 1.0
Extracellular 24 205 1.8
(Extracellular space) (13) (115) (1.7)
(Extracellular matrix) (6) (47) (2.0)
Ribonucleoprotein complex 5 40 2.0
Cytosol 9 78 1.8
aGene ontology terms with more than ﬁve dysregulated genes and
ORP 1:5.
bNumber of genes associated with the GO term among 477 dysregu-
lated genes.
cNumber of genes associated with the GO term among 9982 genes in
G2.
dOdds ratio given by the ratio of the odds of dysregulation of the GO
term to the odds of dysregulation in the overall category (e.g., for lipid
metabolism, OR¼ ð17=ð110 17ÞÞ=ð146=ð2145 146ÞÞ).
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Fig. 1. Number of integration-driven discoveries versus number of
total discoveries. Up- and down-regulated genes were treated sepa-
rately. Total discoveries are genes called signiﬁcant in the meta-anal-
ysis result with a given z threshold. Integration-driven discoveries are
genes that are not signiﬁcant in any of individual results but that are
signiﬁcant in the combined result.
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niﬁcance level.
3.4. Biological implications of identiﬁed genes
Biological aspects of 477 dysregulated genes were explored
using GO terms. We discovered GO terms with high frequency
of dysregulation. The odds of dysregulation was given by the
ratio of the number of dysregulated genes to the number of the
other genes (in G2). Odds ratio (OR) was computed as the ratio
of the odds of dysregulation of the GO term to the odds of
dysregulation of the category to which the GO term belongs
(i.e., biological process, molecular function, or cellular com-
ponent). For example, of 110 genes associated with lipid me-
tabolism, we found 17 dysregulated genes. Since lipid
metabolism belongs to biological process, OR is computed as
ð17=ð110 17ÞÞ=ð146=ð2145 146ÞÞ. GO terms with more
than ﬁve dysregulated genes and ORP 1:5 are listed in Table 3.
Remarkably, inspection of GO terms revealed important
liver-speciﬁc signatures that represent main liver functions
(e.g., lipid metabolism, amino acid metabolism, carbohydrate
metabolism, hormone metabolism, biosynthesis, circulation,
complement component, etc.). About 90% of the corre-
sponding dysregulated genes were down-regulated except for
ribosomal proteins and eukaryotic translation initiation fac-
tors. The term ‘‘intracellular signaling cascade’’ in Table 3
includes MAPKKK, JNK, and JAK/STAT cascades, G-
protein signaling coupled to cAMP, and RAS protein signal
transduction. ‘‘Receptor signaling protein’’ in molecular
function is closely linked to ‘‘intracellular signaling cascade’’
sharing several genes (e.g., small GTPase regulatory/inter-
acting proteins are connected with RAS protein signal
transduction). ‘‘Chemotaxis’’ contains chemokines and
chemokine receptors.
The gene names and quality scores of integration-driven
discoveries of zth ¼ 2:5 were given at http://centi.kribb.re.kr/
MMA. We selected 70 interesting genes from the perspective of
oncogenesis (see Table 4). The list contains previously reported
genes or their related genes (e.g., the same family or a diﬀerent
subunit) including RPL35, PSMD4, EIF3S7, EIF3S8, GSTA2,
NNMT, UGT2B7, PON3, HPD, FGA, C6, C3, ALB, and
CYP7B1, and genes expected to be dysregulated in terms ofliver functions, including TPI1, TRIP6, DGUOK, DUT,
GBE1, FDFT1, ACAT1, ACAA1, ARG1, SERPIN1C,
ALOX15, SCP2, SLC25A20, GSTA3, TPO, SORD, ODC1,
and FUT1.
The list also contains interesting genes not reported in pre-
vious expression proﬁling studies. Some of these genes are
worthy of further investigation in association with HCC. We
illustrate three down-regulated genes: growth hormone recep-
tor (GHR), tissue factor pathway inhibitor-2 (TFPI-2), and
regucalcin or senescence marker protein 30 and two up-regu-
lated genes: membrane cofactor protein (MCP or CD46) and
erythropoietin receptor (EPOR).
Growth harmone receptor has eight diﬀerent 50-untranslated
region variants (V1–V8) and the exclusive expression of V1
variant in adult liver has been reported. Marked or complete
suppression of V1 in HCC as compared to paired normal liver
has also been found [17]. According to Fernandez et al. [18]
and Ji et al. [19], growth hormone (GH) administration to rat
hepatoma cells desensitizes the JAK2/STAT5 pathway, possi-
bly because of the down-regulation of GHR. These ﬁndings
may explain why GH fails to stimulate growth in hepatoma
J. Kyoon Choi et al. / FEBS Letters 565 (2004) 93–100 97cells as it does in other cancer cells [20–23]. Therefore, tran-
scriptional regulation of GHR V1 in HCC is worth the in-
vestigation in association with GH-mediated JAK2/STAT5
signaling.
Tissue factor pathway inhibit-2 inhibits several extracellular
matrix degrading serine proteases and may play a role in
tumor invasion and metastasis. The regulatory role of TFPI-2
in the invasiveness of human lung, prostate and brain cancer
cell was suggested based on its mRNA level [24–26]. It was
also shown that the expression of TFPI-2 is correlated in-
versely with the progression of human gliomas [27]. Since
invasion is a characteristic feature of HCC, the role of TFPI-2
in the HGF-induced invasion of HCC cells [28] is worth the
investigation.
Regucalcin is preferentially expressed in liver. Inagaki and
Yamaguchi [29] suggested that regucalcin plays a suppressive
role in the enhancement of various protein kinase activities
associated with the proliferation of the cloned rat hepatoma
cells. Over-expressing regucalcin in rat hepatoma cell was
shown to result in the signiﬁcant suppression of cell prolifer-
ation and DNA synthesis [30]. Therefore, HCC may deactivate
one of tumor-suppressing factors by decreasing the transcript
level of regucalcin.
Membrane cofactor protein is one of the complement reg-
ulatory proteins and is widely distributed in human organs.
Kinugasa et al. [31], using Western blot analysis, reported that
the protein level of MCP in HCC was signiﬁcantly higher than
that in both liver cirrhosis and chronic hepatitis. Our result
suggests that MCP is regulated at the mRNA level during
tumor progression. HCC may acquire increased MCP ex-
pression and escape from tumor-speciﬁc complement-mediated
cytotoxicity.
Because autonomous erythropoietin (EPO) expression can
mediate the autocrine growth of EPOR-bearing erythrocytes,
the expressions of EPO and EPOR by tumors of other tissues
may also stimulate cancer. Recent studies have reported the
expression of EPOR in various human cancer cells and the
possible contribution of EPO–EPOR pathway to the promo-
tion of cancer [32–34]. EPO is produced mainly in kidney and,
to a lesser extent, in liver. Autocrine role for EPO signaling in
promoting the growth of renal cancers has been suggested [35].
The increase of EPOR in HCC is also notable in that increased
serum EPO level often characterizes HCC.4. Discussion
In our previous study, an eﬀect size model was employed to
analyze microarray data. Here, the eﬀect size method was used
to discover signiﬁcant genes and to conﬁrm the results by in-
terstudy validation from our multi-center microarray studies
on HCC. There are two distinct approaches in eﬀect size
method: a ﬁxed eﬀects model (FEM) and a random eﬀects
model (REM). For a FEM, we assume that the studies under
examination share the common true eﬀect size l, and that the
diﬀerences of the actual eﬀect sizes are due to sampling errors
alone. In a REM, the diﬀerences are due not only to sampling
errors, but also to factors other than chance, such as mea-
surement errors and inherent diﬀerences between studies.
Therefore, each study has its own true eﬀect size, which can be
considered as being sampled from a super-population of pos-
sible studies with the variance of s2.Choosing a suitable model for given studies upon the eﬀect
size method is quite challenging. In this study, the QQ plot led
to the conclusion that the heterogeneity is within normal
sampling error supporting a FEM. However, because this is
merely based on the measure of the magnitude of the hetero-
geneity, we needed to investigate the real cause of the hetero-
geneity. This would be possible by using replicated spots
having non-zero eﬀect sizes. Fortunately, our clone set had 12
such lactotransferrin (LTF) spots. When applying one-way
repeated measures ANOVA to the eﬀect sizes of the data, we
found that the variability between the experiments is larger
than expected from the variability within the experiments (data
not shown). Although we could not extend the conclusion of
the LTF case to every gene without global evidence, this
ﬁnding supports the idea of a REM and presents the potential
problem of estimating the heterogeneity merely based on the Q
statistic.
When we are not sure which model is suitable, Bayesian
would oﬀer uniﬁed modeling approach and allow us to over-
come the debate over the appropriateness of a FEM and a
REM. Another approach to this issue is to select a model a
priori according to the type of inference to be made. FEMs are
appropriate for the inferences that extend only to the studies
included in meta-analysis, whereas REMs facilitate the infer-
ences that generalize beyond the given studies.
During the process of combining multiple microarray da-
tasets, we found that the data integration increased sensitivity
for the detection of small expression changes, which the indi-
vidual analyses were unable to detect. The genes found this
way appeared to be meaningful from the perspective of liver
functions and tumorigenesis of HCC. They also included the
genes that had not been reported in previous microarray
studies, to the best of our knowledge. Furthermore, it ap-
peared that several of these new genes play important roles in
tumor progression, based on the ﬁndings of previous HCC
studies.
Statistical aspect of these integration-driven discoveries was
discussed in [8]. They occur when we put together weak but
consistent eﬀects. They are false negatives by individual
analyses. We believe that collecting separate datasets brings
the same eﬀect of increasing sample size, and that this in-
creased sample size in turn decreases the chance of false
negatives. Another important aspect of integration-driven
discoveries concerns homogeneity between individual study
eﬀects. This fact is supported by the quite large P values of
the Q statistics in Table 4 and ensures that the separate re-
sults are in good agreement. It should also be emphasized
that this interstudy validation does more than simply in-
creasing sample size, because it synthesizes studies performed
under various experimental conditions and study populations.
Thus, it enables us to overcome the limitation of single mi-
croarray studies. The risk of making conclusions based on a
single-set analysis was made apparent by our cross-veriﬁca-
tion analysis.
From these ﬁndings, we propose that the integration of more
than one independent dataset should be encouraged to be
widely used in a variety of microarray applications. By en-
hancing both the reliability and sensitivity of analysis, meta-
analysis would provide an opportunity of unearthing new
target genes that are beyond the reach of conventional single-
set analyses. Moreover, public archives will facilitate a variety
of applications of microarray meta-analyses on larger scales.
Table 4
Known genes selected from integration-driven discoveries
Gene description D1 (SE) D2 (SE) D3 (SE) D4 (SE) Avg (SE) zavg P ðQÞ
30 up-regulated genes
Ribosomal protein L35
(RPL35)
0.885 (0.370) 0.628 (0.309) 0.799 (0.494) 0.702 (0.682) 0.742 (0.204) 3.635 0.95992
Triosephosphate isomerase 1
(TPI1)
0.810 (0.374) 0.546 (0.304) 0.534 (0.489) 0.740 (0.499) 0.646 (0.195) 3.306 0.9427
Thyroid hormone receptor
interactor 6 (TRIP6)
0.705 (0.376) 0.537 (0.304) 0.426 (0.487) 1.089 (0.539) 0.639 (0.198) 3.233 0.79383
H2A histone family, member
Z
0.804 (0.374) 0.385 (0.298) 0.613 (0.490) 0.855 (0.460) 0.611 (0.191) 3.194 0.77173
Proteasome 26S subunit
(PSMD4)
0.777 (0.367) 0.448 (0.299) 0.571 (0.489) 0.720 (0.470) 0.601 (0.191) 3.143 0.90536
Deoxyguanosine
kinase (DGUOK)
0.477 (0.466) 0.615 (0.305) 0.565 (0.490) 1.239 (0.593) 0.657 (0.212) 3.106 0.76051
MGC11287 similar to
ribosomal protein S6 kinase
0.725 (0.405) 0.575 (0.304) 0.619 (0.491) 0.548 (0.508) 0.615 (0.200) 3.069 0.99076
Transmembrane 9
superfamily member 1
0.934 (0.443) 0.404 (0.301) 0.547 (0.489) 0.825 (0.475) 0.613 (0.201) 3.049 0.74676
Eukaryotic translation
initiation factor 3, subunit
7 (EIF3S7)
0.744 (0.398) 0.736 (0.305) 0.133 (0.487) 0.596 (0.624) 0.616 (0.205) 3.01 0.74289
DUTP pyrophosphatase
(DUT)
0.817 (0.417) 0.512 (0.300) 0.148 (0.485) 1.018 (0.512) 0.598 (0.200) 2.985 0.59423
Eukaryotic translation
initiation factor 3, subunit 8
(EIF3S8)
0.921 (0.372) 0.308 (0.297) 0.571 (0.489) 0.640 (0.476) 0.565 (0.192) 2.948 0.63818
Corticotropin releasing
hormone receptor 1
0.687 (0.460) 0.516 (0.300) 0.214 (0.489) 1.620 (0.653) 0.612 (0.211) 2.893 0.36504
Erythropoietin receptor 0.810 (0.467) 0.696 (0.307) 0.358 (0.486) 0.285 (0.502) 0.588 (0.207) 2.842 0.81646
Glucan (1,4-alpha-),
branching enzyme 1 (GBE1)
0.637 (0.381) 0.361 (0.301) 0.888 (0.498) 0.477 (0.471) 0.533 (0.194) 2.743 0.8195
Kinesin family member 3C 0.532 (0.366) 0.379 (0.298) 0.830 (0.495) 0.988 (0.709) 0.548 (0.201) 2.731 0.79239
Peroxisome biogenesis factor
13
0.523 (0.378) 0.342 (0.307) 1.046 (0.501) 0.576 (0.493) 0.538 (0.197) 2.728 0.69566
Serine/threonine kinase 25
(oxidant stress response
kinase1)
0.912 (0.378) 0.513 (0.300) 0.021 (0.484) 0.517 (0.600) 0.541 (0.199) 2.717 0.54621
NADH dehydrogenase
(ubiquinone) 1 alpha
0.638 (0.362) 0.401 (0.298) 0.638 (0.490) 0.481 (0.463) 0.515 (0.190) 2.711 0.95439
Farnesyl-diphosphate
farnesyltransferase 1 (FDFT1)
0.508 (0.407) 0.353 (0.301) 0.985 (0.499) 0.665 (0.506) 0.540 (0.200) 2.705 0.74079
Thioredoxin 0.445 (0.358) 0.364 (0.297) 0.915 (0.497) 0.651 (0.476) 0.514 (0.190) 2.698 0.79505
Transcription elongation
factor B (SIII), polypeptide
0.631 (0.388) 0.255 (0.296) 0.468 (0.488) 1.141 (0.491) 0.523 (0.195) 2.687 0.47697
Heterogeneous nuclear
ribonucleoprotein A1
0.531 (0.425) 0.595 (0.312) 0.124 (0.486) 0.802 (0.474) 0.537 (0.202) 2.658 0.78477
APEX nuclease (multifunc-
tional DNA repair enzyme)
0.670 (0.429) 0.601 (0.315) 0.381 (0.498) 0.332 (0.487) 0.531 (0.205) 2.588 0.93784
Membrane cofactor protein 0.035 (0.486) 0.714 (0.304) 0.693 (0.500) 0.437 (0.524) 0.539 (0.210) 2.568 0.67366
MutS (E. coli) homolog 6 0.385 (0.375) 0.744 (0.305) 0.233 (0.485) 0.331 (0.468) 0.496 (0.194) 2.563 0.76065
Capping protein (actin
ﬁlament), gelsolin-like
0.467 (0.370) 0.638 (0.306) 0.556 (0.489) 0.144 (0.476) 0.496 (0.194) 2.557 0.85334
Translocating chain-asso-
ciating membrane protein
(TRAM)
0.446 (0.376) 0.693 (0.304) 0.015 (0.484) 0.652 (0.549) 0.506 (0.198) 2.554 0.68194
DEAD/H box polypeptide
9 (RNA helicase A)
0.652 (0.376) 0.374 (0.297) 0.621 (0.490) 0.448 (0.593) 0.501 (0.198) 2.523 0.93803
Myosin, heavy polypeptide 3 0.168 (0.438) 0.549 (0.304) 0.561 (0.492) 1.052 (0.593) 0.527 (0.208) 2.529 0.6901
Kinesin family member 3C 0.448 (0.480) 0.574 (0.301) 0.554 (0.506) 0.423 (0.509) 0.522 (0.208) 2.511 0.99238
40 down-regulated genes
Multiple endocrine
neoplasia I
)0.717 (0.383) )0.764 (0.316) )1.230 (0.513) )1.061 (0.470) )0.875 (0.199) )4.388 0.81896
Glutathione S-transferase
A2 (GSTA2)
)0.826 (0.368) )0.791 (0.317) )0.591 (0.490) )0.970 (0.466) )0.800 (0.196) )4.091 0.95599
Nicotinamide N-methyl-
transferase (NNMT)
)0.622 (0.368) )0.687 (0.303) )1.259 (0.508) )0.285 (0.573) )0.707 (0.199) )3.549 0.61856
Core-binding factor, runt
domain (MTG16)
)0.855 (0.445) )0.555 (0.311) )1.177 (0.531) )0.837 (0.636) )0.761 (0.216) )3.522 0.774
UDP glycosyltransferase
2 family, B7 (UGT2B7)
)0.849 (0.369) )0.453 (0.299) )0.570 (0.495) )1.334 (0.572) )0.690 (0.197) )3.496 0.54335
Growth hormone receptor )0.609 (0.374) )0.356 (0.297) )1.191 (0.505) )1.191 (0.503) )0.674 (0.195) )3.461 0.35076
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Table 4 (continued)
Gene description D1 (SE) D2 (SE) D3 (SE) D4 (SE) Avg (SE) zavg P ðQÞ
Paraoxonase 3 (PON3) )0.460 (0.383) )0.762 (0.305) )0.843 (0.502) )0.441 (0.465) )0.639 (0.196) )3.265 0.86687
Acetyl-coenzyme A acetyl-
transferase 1 (ACAT1)
)0.539 (0.399) )0.636 (0.309) )0.381 (0.494) )1.344 (0.557) )0.662 (0.204) )3.246 0.58791
4-Hydroxyphenylpyruvate
dioxygenase (HPD)
)0.390 (0.382) )0.544 (0.322) )1.103 (0.504) )1.053 (0.552) )0.663 (0.206) )3.226 0.59179
Arginase, liver (ARG1) )0.969 (0.415) )0.652 (0.303) )0.379 (0.489) )0.415 (0.454) )0.635 (0.197) )3.221 0.76255
Fibrinogen, A alpha (FGA) )0.718 (0.377) )0.719 (0.308) )0.644 (0.501) )0.250 (0.458) )0.623 (0.195) )3.197 0.84366
Complement component
6 (C6)
)0.821 (0.426) )0.433 (0.302) )1.321 (0.597) )0.567 (0.465) )0.652 (0.204) )3.19 0.57828
Antithrombin III
(SERPINC1)
)0.467 (0.383) )0.608 (0.302) )1.081 (0.503) )0.390 (0.445) )0.601 (0.193) )3.11 0.73923
Neural cell adhesion
molecule 1
)0.671 (0.462) )0.668 (0.306) )0.815 (0.508) )0.336 (0.489) )0.634 (0.207) )3.066 0.91506
Tissue factor pathway
inhibitor 2
)0.562 (0.411) )0.547 (0.300) )0.628 (0.490) )0.816 (0.494) )0.608 (0.199) )3.055 0.97225
Albumin (ALB) )0.712 (0.365) )0.464 (0.299) )0.675 (0.491) )0.475 (0.447) )0.565 (0.189) )2.98 0.94691
Complement component 3
(C3)
)0.783 (0.367) )0.486 (0.299) )0.763 (0.498) )0.245 (0.485) )0.572 (0.193) )2.964 0.7974
Microsomal triglyceride
transfer protein
)0.923 (0.398) )0.377 (0.301) )0.213 (0.488) )1.103 (0.528) )0.590 (0.199) )2.962 0.43322
Arachidonate 15-lipoxy-
genase (ALOX15)
)0.596 (0.380) )0.664 (0.306) )0.926 (0.497) 0.014 (0.504) )0.583 (0.198) )2.948 0.58218
Transcription factor (TFIIB) )0.435 (0.376) )0.491 (0.306) )0.720 (0.492) )0.979 (0.521) )0.583 (0.198) )2.945 0.82523
Sterol carrier protein X
(SCP2)
)0.283 (0.373) )0.753 (0.309) )0.110 (0.484) )1.043 (0.469) )0.572 (0.194) )2.944 0.41405
Lymphocyte antigen
6 complex, locus E
0.065 (0.372) )0.731 (0.308) )1.031 (0.500) )0.957 (0.525) )0.584 (0.198) )2.943 0.20521
Carnitine/acylcarnitine
translocase (SLC25A20)
)1.091 (0.457) )0.374 (0.312) )0.207 (0.494) )1.132 (0.530) )0.614 (0.210) )2.928 0.3452
Glutathione S-transferase
A3 (GSTA3)
)0.823 (0.374) )0.552 (0.300) )0.508 (0.488) )0.235 (0.451) )0.559 (0.191) )2.923 0.79564
Acetyl-coenzyme A
acyltransferase 1 (ACAA1)
)0.187 (0.366) )0.707 (0.330) )0.812 (0.494) )0.715 (0.470) )0.572 (0.199) )2.874 0.65876
Thyroid peroxidase (TPO) )0.294 (0.462) )0.341 (0.327) )1.056 (0.509) )1.300 (0.530) )0.619 (0.216) )2.867 0.30696
Sorbitol dehydrogenase
(SORD)
)0.680 (0.405) )0.512 (0.300) )0.331 (0.490) )0.714 (0.470) )0.558 (0.196) )2.841 0.93197
Carboxypeptidase B2
(plasma)
)0.314 (0.356) )0.601 (0.301) )0.773 (0.493) )0.537 (0.457) )0.534 (0.190) )2.814 0.88123
Jagged 1 hematopoiesis )1.023 (0.455) )0.733 (0.305) 0.045 (0.492) )0.220 (0.476) )0.564 (0.203) )2.772 0.33685
Angiogenin, ribonuclease
(ANG)
)0.730 (0.365) )0.291 (0.296) )1.043 (0.500) )0.283 (0.443) )0.515 (0.189) )2.722 0.51106
Regucalcin (senescence
marker protein-30)
)0.906 (0.397) )0.316 (0.297) )0.285 (0.490) )0.793 (0.492) )0.530 (0.196) )2.705 0.58168
cdc-like kinase 2 (CLK2) )1.271 (0.520) )0.395 (0.316) )0.417 (0.491) )0.551 (0.502) )0.576 (0.214) )2.693 0.52682
Claudin 1 (senescence-
associated epithelial
membrane protein)
)0.783 (0.386) )0.267 (0.300) )1.074 (0.501) )0.241 (0.466) )0.515 (0.194) )2.648 0.4299
Chaperonin containing
TCP1, subunit 4 (delta)
)0.502 (0.359) )0.335 (0.300) )0.774 (0.493) )0.890 (0.583) )0.518 (0.196) )2.636 0.78911
Integrin, beta 1 (ﬁbronectin
receptor)
)0.784 (0.367) )0.327 (0.297) )0.928 (0.497) )0.110 (0.441) )0.496 (0.189) )2.621 0.48275
Ornithine decarboxylase
1 (ODC1)
)0.587 (0.367) )0.584 (0.301) )0.826 (0.494) 0.172 (0.484) )0.501 (0.193) )2.595 0.47615
Cathepsin O )0.342 (0.388) )0.632 (0.309) )0.554 (0.490) )0.435 (0.470) )0.510 (0.197) )2.592 0.94509
Cytochrome P450,
subfamily VIIB polypeptide
1 (CYP7B1)
)0.495 (0.365) )0.596 (0.301) )0.558 (0.490) )0.177 (0.457) )0.490 (0.191) )2.567 0.89381
Vanin 1 )0.585 (0.361) )0.232 (0.326) )0.953 (0.498) )0.539 (0.483) )0.505 (0.198) )2.546 0.66803
Fucosyltransferase 1 (FUT1) )0.312 (0.356) )0.638 (0.302) )0.556 (0.489) )0.382 (0.575) )0.496 (0.196) )2.534 0.90936
Of integration-driven discoveries with zth ¼ 2:5, 30 up-regulated and 40 down-regulated genes were selected to be displayed. D1–D4, eﬀect size for
D1–D4; S.E., standard error; Avg, average eﬀect size calculated based on FEM; zavg, z score of average eﬀect size; P ðQÞ, P value of Q statistic. Larger
P ðQÞ indicates that the eﬀect sizes are more homogeneous. Genes mentioned in text are indicated by bold type.
J. Kyoon Choi et al. / FEBS Letters 565 (2004) 93–100 99Our work established the methodology of using an eﬀect size
model for microarray meta-analysis and demonstrated its ef-
fectiveness with an application to HCC studies. It was shown
that the meta-analysis could oﬀer more exact and extended
clues into liver carcinogenesis. Here, we reported upon genes
newly discovered using our method and some of the genes that
call for further investigation. We believe that these genesidentiﬁed by the integration of expression proﬁles will helpfully
expand our knowledge of the mechanism of HCC progression.Acknowledgements: This work was supported by Grant No. FG-5-01
of the 21C Frontier Functional Human Genome Project from the
Ministry of Science & Technology of Korea. The authors thank Drs.
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